

CMA response:

HEALTH CANADA CONSULTATION ON CANADIAN DRUGS AND SUBSTANCES STRATEGY

December 4, 2018

The Canadian Medical Association (CMA) is the national voice of Canadian physicians. Founded in 1867, the CMA's mission is to empower and care for patients and its vision is to support a vibrant profession and a healthy population.

On behalf of its more than 85,000 members and the Canadian public, the CMA performs a wide variety of functions. Key functions include advocating for health promotion and disease/injury prevention policies and strategies, advocating for access to quality health care, facilitating change within the medical profession, and providing leadership and guidance to physicians to help them influence, manage and adapt to changes in health care delivery.

The CMA is a voluntary professional organization representing the majority of Canada's physicians and comprising 12 provincial and territorial divisions and over 60 national medical organizations.

The Canadian Medical Association (CMA) is pleased to provide this submission in response to Health Canada's consultation on new and innovative ideas on how to further strengthen the federal government's health-focussed approach to substance use issues through the Canadian Drugs and Substances Strategy (CDSS)¹

Question 1

What sorts of circumstances do you see within your networks, communities or in society that you think contribute to problematic substance use?

There are multiple factors that contribute to problematic substance use. It is a serious, chronic and relapsing medical condition for which there are effective treatments. However, using the social determinants as a framework, most health promotion and prevention efforts will take place outside of the traditional health and medical care services.²

Many Canadians face barriers in their physical, social and economic environments which can contribute to problematic substance use, and certain populations are at higher risk given these circumstances. For example, early childhood is a critical time in the social, emotional, cognitive and physical development of a person. Experiences in early life can 'get under the skin', changing the ways that genes are expressed. Negative experiences such as poverty or family or parental violence can have significant impacts on this important period of development.³

What is necessary is a coordinated effort across government sectors to ensure that all policy decisions serve to increase opportunities for health. Improving population health and reducing inequities should be an overall objective for all governments in Canada.

Question 2

Have you seen or experienced programs, practices or models at the local or regional level that could be expanded, or implemented more broadly, to improve circumstances or social determinants of health that influence substance use?

Income is critical to individual health and is closely linked to many of the other social determinants of health. These include but are not limited to: education, employment, early childhood development, housing, social exclusion, and physical environment.⁴ Adequate consideration must be given to the social and economic determinants of health, factors such as income and housing that have a major impact on health outcomes. Minimizing poverty should be a top priority.

In 2015, the CMA passed a resolution endorsing the concept of a basic income guarantee, which is a cash transfer from government to citizens not tied to labour market participation.⁵ It ensures sufficient income to meet basic needs and live with dignity, regardless of employment status. A basic income guarantee has the potential to alleviate or even eliminate poverty. It has the potential to reduce the substantial, long-term social consequences of poverty, including higher crime rates and fewer students achieving success in the educational system.

Drug use must not be treated with a criminal justice approach, which does not address the determinants of drug use, treat addictions, or reduce the harms associated with drug use. More investments need to be made in prevention, harm reduction and treatment, keeping individuals out of the criminal justice system. Drug use is a complex issue, and collaboration among health and public safety professionals, and society at large, is essential.⁶

Question 3

What needs to change to make sure that opioid medications are being provided and used appropriately, based on the needs of each patient?

Policy makers must recognize that prescription opioids are an essential tool in the alleviation of pain and suffering, particularly in palliative and cancer care.⁷ Doctors support patients in the management of acute and chronic pain, as well as problematic substance use, and as such have long been concerned about the harms associated with opioid use.⁸

Treatment options and services for both problematic substance use as well as pain management are woefully under-resourced in Canada. Experts believe that improved access to specialized pain treatment could reduce inappropriate use of pain medications. Current best practices in pain management include care by an interprofessional team that could include physiotherapists, occupational therapists, psychologists and other health professionals; non-pharmaceutical interventions such as therapy for trauma and social pain, social supports and coping strategies; appropriate pharmaceutical prescription options, covered by provincial formularies; and a focus on patient participation and empowerment.¹⁵ Availability and access of these critical resources varies by jurisdiction and region. The federal government should prioritize the expansion of these services.

It is also important to support clinicians in their practice. The 2017 Opioid Prescribing Guidelines need to be kept current through ongoing funding.⁹ Physicians require tools, including those that facilitate monitoring of effectiveness and tolerance by tracking pain and physical function; screening for past and current substance use; screening for depression; and, tapering of problematic or ineffective doses.¹⁰

Question 4

How can we make sure that those who require prescription opioids to manage their pain have access to them, without judgement or discrimination?

Governments need to incorporate the identification and elimination of stigma as a quality of care indicator in the ongoing monitoring of health system performance at all levels.¹¹ They also need to implement and evaluate national public awareness and education strategies to counteract the stigma associated with substance use issues as well as enforcing legislation and regulations to guard against discrimination against people with mental and substance use issues.

Health professionals need to have access to education on pain management and treatment of problematic substance use, recognizing both issues as serious medical conditions for which there are effective treatments.¹²

Question 5

Which kinds of messages would work best to help Canadians understand the serious harms that can result from stigma around substance use?

A recent report from the Canadian Centre on Substance Use and Addiction (CCSA) and Public Safety Canada cited stigma as “an enormous barrier to individuals seeking and maintaining treatment.”¹³ Even though there is broad recognition that we are in a public health crisis, until very recently the focus of the federal National Anti-Drug Strategy was heavily skewed towards a criminal justice approach rather than a public health approach with an emphasis on enforcement, as opposed to prevention, treatment and harm reduction.^{Error! Bookmark not defined.} This has serious implications in how society views people who use drugs. As noted in the CCSA-Public Safety report, “Language matters. Speak about people first, with compassion and respect.”¹³

A stigma reduction strategy must be core to the activities of the federal government.¹⁴ Stigma involves thoughts, emotions and behaviours; thus, a comprehensive approach includes interventions to target each of these dimensions at both the individual and population level. The strategy should include aspects of:

- * Public awareness and education to facilitate understanding about the importance of early

- diagnosis, treatment, recovery and prevention;
- * Enhanced provider/student education and support;
- * Policy analysis and modification of discriminatory legislation;
- * Support for a strong voluntary sector to voice the concerns of patients and their families;
- * Exposure to positive spokespeople (e.g. prominent Canadians) who have mental illness and/or addiction in order to highlight success stories;
- * Researching stigma.

Question 6

How can we best act to reduce stigma across the country?

Engagement with people who use drugs to help them share their stories and experiences with stigma with the public

Question 7

What would you recommend to improve substance use treatment services in Canada?

This challenge requires a complex and multifaceted solution; and to further this aim, Canada needs a comprehensive national strategy to address the harms associated with psychoactive drugs in Canada, whether illegal or prescription-based, complementing existing strategies to address the harms associated with the other two legal drugs - alcohol and tobacco.¹⁵ This comprehensive approach is necessary, as isolated measures can have unintended consequences, such as under-medicating people that require a medical treatment or constraining people to seek illegal drugs as an option when medications are made tamper-resistant. One of the fundamental principles of health care is that it be patient centred.¹¹ CMA defines patient-centred care as “seamless access to the continuum of care in a timely manner ... that takes into consideration the individual needs and preferences of the patient and his/her family and treats the patient with respect and dignity.”

It is essential that patients be core members of the health care team, working with health care providers to address their individual needs, preferences and aspirations and to seek their personal paths to well-being. Physicians and other health professionals can help patients make choices about their treatment and can provide information and support to patients and their families as they seek to cope with the effects of problematic use and live functional lives. The health care provider community needs tools to assist in the reduction of stigma, access to resources and supportive environments.

Question 8

What obstacles or barriers do people face when they want to access treatment in Canada?

Obstacles to treatment include the lack of publicly-funded treatment centres, access to locations for remote areas, limited number of beds available, the cost of private treatment (lack of insurance), and stigma. The CMA supports the enhancement of access to options for treatment that address different needs.¹⁵ Treatment programs must be coordinated and patient-centred, and address physical, psychological, social and spiritual circumstances. For example, it is important that treatment programs be culturally relevant for Indigenous communities.

Question 10

In addition to current harm reduction initiatives – such as supervised consumption sites, needle exchange programs – what other harm reduction services should governments consider implementing in Canada?

There is a dire need to address harm reduction in prisons. Even back in 2005, the CMA recommended to the Correctional Service of Canada that it develop, implement and evaluate a pilot needle exchange

program in prison(s) under its jurisdiction. These services are not widespread and accessible to prison populations. In Canada, people in prison face far greater risk of HIV and hepatitis C infection because they are denied access to sterile injection equipment as a harm reduction strategy.

Hospitals need to incorporate harm reduction strategies as well, allowing people who use drugs to access much needed health services.

Question 12

How can we better bring public health and law enforcement together to explore ways to reduce the cycle of involvement for people who use substances with the criminal justice system?

Training for police and other frontline criminal justice and corrections workers in how to interact with people with substance use issues is essential. The CMA believes that the government must take a broad public health policy approach. Changes to the criminal law affecting cannabis must not promote normalization of its use and must be tied to a national drug strategy that promotes awareness and prevention and provides for comprehensive treatment. **Error! Bookmark not defined.**

The CMA recognized that a blanket prohibition of possession for teenagers and young adults would not reflect current reality or a harm reduction approach. The possibility that a young person might incur a lifelong criminal record for periodic use or possession of small amounts of cannabis for personal use means that the long-term social and economic harms of cannabis use can be disproportionate to the drug's physiological harm.¹⁶

Question 13

What further steps can the federal government take to better address current regulation and enforcement priorities, such as addressing organized drug crime and the dangerous illegal drugs like fentanyl being brought into Canada?

The federal government must continue to work closely with the RCMP, local and provincial law enforcement agencies, Canada Post, the Canadian Border Services Agency, Crown attorneys, the Canadian military, and international health officials and law enforcement agencies to address this issue. This topic was covered in the recent CCSA/Public Safety Canada report. **Error! Bookmark not defined.**

Question 14

Recognizing Indigenous rights and self-determination, how can all governments work together to address the high rates of problematic substance use faced by some Indigenous communities?

Difficulties in access are particularly acute for Canada's Indigenous peoples.¹⁷ Many live in communities with limited access to health care services, sometimes having to travel hundreds of miles to access care. Additionally, there are jurisdictional challenges; many fall through the cracks between the provincial and federal health systems.

While geography is a significant barrier for Indigenous peoples, it is not the only one. Indigenous peoples living in Canada's urban centres also face difficulties. Poverty, social exclusion and discrimination can be barriers to needed health care. Of all federal spending on indigenous programs and services only 10% is allocated to urban Aboriginals. This means that Aboriginals living in urban areas are unable to access programs such as Aboriginal head start, or alcohol and drug services, which would be available if they were living on reserve. Further, even when care is available it may not be culturally appropriate.

Canada's indigenous peoples tend to be over-represented in populations most at risk and with the greatest need for care, making the lack of access a much greater issue for their health status. It is important that problematic substance use programs be culturally relevant for Indigenous communities.

It is clear that the First Nations and Inuit peoples of Canada experience mental illness, problematic substance use and poor mental health at rates exceeding that of other Canadians.¹⁴ Individual, community and population level factors contribute to this including socioeconomic status, social environment, child development, nutrition, maternal health, culture and access to health services. The urgent need to work with these communities and identify the structures and interventions to reduce the burden of mental illness and substance use is critical to the health and wellness and future of First Nations and Inuit peoples.

Enhanced federal capacity should be created through First Nations and Inuit Health that will provide increased funding and support for First Nations and Inuit community health strategies. The establishment of a working groups comprised of First Nations and Inuit health experts and accountable to First Nations and Inuit leadership is essential for the success of this initiative. Both expert and resource supports are integral elements to facilitate and encourage culturally appropriate strategies and programming in these communities.

Question 15

What can we learn from Indigenous approaches to problematic substance use, such as using holistic approaches, that may help inform activities under the CDSS?

The federal government must consult First Nations, Inuit, and Métis representatives to develop programs that are culturally relevant and appropriate for Indigenous communities.

Question 16

How can governments, and the health, social, and law enforcement sectors design more effective substance use policies and programs for at-risk populations?

The government must identify and consult those communities and populations most at risk. This includes First Nations, Inuit, and Métis representatives, community advocates, municipalities, and provincial and local public health officers. Data that describes rates of use and issues specific to each at risk group is important to be able to better understand and address needs.

Question 17

What are effective policies and programs to help improve access to prevention, treatment, and harm reduction services for at-risk populations?

There are innovative approaches to address the needs of high-volume users as well as at-risk populations. As many of these involve greater integration between health and the community sector and attention to issues not traditionally funded through health care payment systems, there is a need to provide access to funds to enable these innovations to continue and be spread across the country.¹⁸

A targeted, integrated approach to identify communities in need is required and this must be based on reliable community data (i.e., meaningful use of patient data) which can be used to integrate resources to improve health status. For example, the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) is Canada's first multi-disease electronic medical records (EMR) surveillance and research system that allows family physicians, epidemiologists and researchers from across the country to better understand and manage chronic care conditions for their patients. Health information is collected from EMRs in the offices of participating primary care providers (e.g. family physicians) for the purposes of improving the quality of care for Canadians suffering from chronic and mental health conditions and three neurologic conditions including Alzheimer's and related dementias. CPCSSN makes it possible to securely collect and report on vital information from Canadians' health records to improve the way these chronic diseases and neurologic conditions are managed (<http://cpcssn.ca/>).

Question 18

What urgent gaps related to substance use (in terms of data, surveillance, and/or research) need to be addressed in Canada?

Improvements are being made in the collection of data in Canada. This is crucial to be able to assess the harms and track the trends and impact of the introduction of policy changes.¹⁵ As well, the government must continue to improve the ability of the Public Health Agency of Canada, the Canadian Institute of Health Information, the chief coroners of Canada and related agencies to collect, analyze and report data.

One such program is the surveillance system in the United States called RADARS (Researched Abuse, Diversion and Addiction-Related Surveillance system) that is “a surveillance system that collects product- and geographically-specific data on abuse, misuse, and diversion of prescription drugs.”¹⁹ It surveys data involving opioids including poison control centres, treatment programs, on the “illicit acquisition or distribution of prescription opioids, stimulants, and other prescription drugs of interest from entities investigating drug diversion cases,” among other opioid-related issues.

The CMA has recommended that all levels of government work with one another and with health professional regulatory agencies to develop a pan-Canadian system of real-time prescription monitoring.²⁰ As a first step, the CMA recommends the establishment of consistent national standards for prescription monitoring.

Prescription Monitoring Programs (PMP) should be compatible with existing electronic medical and pharmacy record systems and with provincial pharmaceutical databases. Participation in prescription monitoring programs should not impose an onerous administrative burden on health care providers. PMPs should not deter physicians from using controlled medications when necessary. Further, PMPs are a valuable component in addressing the gaps related to substance use.²¹

Question 19

How can we use research tools to better identify emerging substance use issues as early as possible?

See above response to question 18 - “RADARS”

¹ Government of Canada. *Consultation on strengthening Canada’s approach to substance use issues*. Ottawa: Health Canada; 2018. Available: <https://www.canada.ca/en/health-canada/programs/consultation-strengthening-canada-approach-substance-use-issues.html> (accessed 2018 Sep 5).

² Canadian Medical Association (CMA). *Health in all policies*. Ottawa: The Association; 2015 Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD15-10.pdf> (accessed 2018 Nov 26).

³ Canadian Medical Association (CMA). *Early childhood development*. Ottawa: The Association; 2015. Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD15-03.pdf> (accessed 2018 Nov 26).

⁴ Canadian Medical Association (CMA). *Canadian Medical Association Submission on Motion 315 (Income Inequality)*. Ottawa: The Association; 2013. Available: <http://policybase.cma.ca/dbtw-wpd/BriefPDF/BR2013-07.pdf> (accessed 2018 Nov 26).

⁵ Canadian Medical Association (CMA). *CMA’s recommendations for effective poverty reduction strategies*. Ottawa: The Association; 2017. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2017-04.pdf> (accessed 2018 Nov 26).

⁶ Canadian Medical Association (CMA). *Bill C-2 An Act to amend the Controlled Drugs and Substances Act*. Ottawa: The Association; 2015. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2015-11.pdf> (accessed 2018 Nov 26).

-
- ⁷ Canadian Medical Association (CMA). *Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada*. Ottawa: The Association; 2016. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2017-15.pdf> (accessed: 2018 Nov 26).
- ⁸ Canadian Medical Association (CMA). *Non-prescription availability of low-dose codeine products*. Ottawa: The Association; 2017. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2018-04.pdf> (accessed 2018 Nov 26).
- ⁹ Canadian Medical Association (CMA). *Health Canada consultation on restriction of marketing and advertising of opioids*. Ottawa: The Association; 2018. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2018-13.pdf> (accessed 2018 Nov 26).
- ¹⁰ Canadian Medical Association (CMA). *Harms associated with opioids and other psychoactive prescription drugs*. Ottawa: The Association; 2015. Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD15-06.pdf> (accessed 2018 Nov 26).
- ¹¹ Canadian Medical Association (CMA). *Joint Canadian Medical Association & Canadian Psychiatric Association Policy - Access to mental health care*. Ottawa: The Association; 2016. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf> (accessed 2018 Nov 26).
- ¹² Canadian Medical Association (CMA). *Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada*. Ottawa: The Association; 2017. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2017-15.pdf> (accessed 2018 Nov 26).
- ¹³ Public Safety Canada, Canadian Centre on Substance Use and Addiction. *2018 Law Enforcement Roundtable on the Opioid Crisis. Meeting Summary*. Ottawa; 2018. Available: https://www.publicsafety.gc.ca/cnt/rsrscs/pblctns/lw-nfrcmnt-rndtbl-pd-crss-2018/index-en.aspx?utm_source=stakeholders&utm_medium=email&utm_campaign=opioidcrisis (accessed 2018 Nov 29).
- ¹⁴ Canadian Medical Association (CMA). *Study on Mental Health, Mental Illness and Addiction in Canada: Supplementary Submission to the Senate Standing Committee on Social Affairs, Science and Technology*. Ottawa: The Association; 2006. Available: <http://policybase.cma.ca/dbtw-wpd/BriefPDF/BR2006-01.pdf> (accessed 2018 Nov 29).
- ¹⁵ Canadian Medical Association (CMA). *Harms associated with opioids and other psychoactive prescription drugs*. Ottawa: The Association; 2015. Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD15-06.pdf> (accessed 2018 Nov 2018).
- ¹⁶ Canadian Medical Association (CMA). *Bill C-45: The Cannabis Act*. Ottawa: The Association; 2017. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2017-09.pdf> (accessed 2018 Nov 28).
- ¹⁷ Canadian Medical Association (CMA). *Ensuring equitable access to health care: Strategies for governments, health system planners, and the medical profession*. Ottawa: The Association; 2014. Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD14-04.pdf> (accessed 2018 23 Nov).
- ¹⁸ Canadian Medical Association (CMA). *Submission to Advisory Panel on Healthcare Innovation*. Ottawa: The Association; 2014. Available: <http://policybase.cma.ca/dbtw-wpd/Briefpdf/BR2015-06.pdf> (accessed 2018 Nov 29).
- ¹⁹ Radars System. 2018. Available: <https://www.radars.org/> (accessed: 2018 Nov 29).
- ²⁰ Canadian Medical Association (CMA). *Harms associated with opioids and other psychoactive prescription drugs*. Ottawa: The Association; 2015 Available: <http://policybase.cma.ca/dbtw-wpd/Policypdf/PD15-06.pdf> (accessed 2018 Dec 4).
- ²¹ Sproule B. *Prescription Monitoring Programs in Canada: Best Practice and Program Review*. Ottawa, ON, 2015 Canadian Centre on Substance Abuse. Available: <http://www.ccsa.ca/Resource%20Library/CCSA-Prescription-Monitoring-Programs-in-Canada-Report-2015-en.pdf> (accessed 2018 Dec 4).